Kidney Week

Abstract: FR-PO0066

Association of Metabolites in Dietary Intervention Trials with ADPKD Progression

Session Information

• ADPKD and Cystic Kidney Disease - 2
  October 23, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Genetic Diseases of the Kidneys

• 1201 Genetic Diseases of the Kidneys: Cystic (Monogenic)

Authors

• Ozekin, Yunus, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Yunus Ozekin, PhD

• Steele, Cortney, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Cortney Steele, PhD

• Klawitter, Jelena, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Jelena Klawitter, PhD

• Little, Megan, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Megan Little

• Coleman, Erin R., University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Erin R. Coleman, MPH

• You, Zhiying, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Zhiying You, MD, PhD

• Hopp, Katharina, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Katharina Hopp, PhD

• Chonchol, Michel, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Michel Chonchol, MD, FASN

• Nowak, Kristen L., University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Kristen L. Nowak, PhD, MPH

Background

Prior studies have identified metabolites associated with kidney growth and progression of ADPKD. To better understand how metabolites prior to dietary interventions associate with ADPKD progression, we performed a metabolomics analysis of participants from two dietary weight loss intervention trials: a time restricted eating (TRE vs. healthy eating advice) and daily caloric restriction (DCR vs. standard of care control) intervention.

Methods

Baseline (BL) EDTA plasma samples were obtained from 45 participants with ADPKD enrolled in randomized, controlled TRE (n=10 active; n=13 control) and DCR (n=11 active; n=11 control) dietary intervention studies and analyzed via untargeted metabolomics. Linear regression models were developed to associate baseline metabolites with clinical outcomes: height-adjusted total kidney volume (htTKV), percent weight change, and estimated glomerular filtration rate (eGFR) slope, controlling for covariates.

Results

308 metabolites passed filtration and were tested for significance. Linear regression models identified several key baseline metabolites significantly associated with outcomes of htTKV, percent weight change, and eGFR slope, regardless of treatment (Fig. 1A-C).

Conclusion

Regardless of dietary intervention mechanism, we identified several key biomarkers that associate with ADPKD progression and weight loss success in obese participants. These findings provide evidence that metabolic state influences clinical trajectory; thus, metabolites may have utility in predicting both ADPKD progression and response to dietary intervention.

Forest plots showing from fully adjusted linear regression models of baseline metabolite associations with outcomes of (A) change in htTKV, (B) percent weight change, and (C) change in eGFR slope in pooled dietary intervention participants.

Funding

• NIDDK Support